The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses

Cameron P. Simmons, Guy E. Thwaites, Nguyen Than Ha Quyen, Tran Thi Hong Chau, Pham Phuong Mai, Nguyen Thi Dung, Kasia Stepniewska, Nicholas J. White, Tran Tinh Hien, Jeremy Farrar

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Outcome from tuberculous meningitis (TBM) is believed to be dependent on the severity of the intracerebral inflammatory response. We have recently shown that dexamethasone improved survival in adults with TBM and postulated that the clinical effect would be associated with a measurable systemic and intracerebral impact on immunological markers of inflammation. Prolonged inflammatory responses were detected in all TBM patients irrespective of treatment assignment (placebo or dexamethasone). The inflammatory response in the cerebrospinal fluid was characterized by a leukocytosis (predominantly CD3+CD4 + T lymphocytes, phenotypically distinct from those in the peripheral blood), elevated concentrations of inflammatory and anti-inflammatory cytokines, chemokines, and evidence of prolonged blood-brain barrier dysfunction. Dexamethasone significantly modulated acute cerebrospinal fluid protein concentrations and marginally reduced IFN-γ concentrations; other immunological and routine biochemical indices of inflammation were unaffected. Peripheral blood monocyte and T cell responses to Mycobacterium tuberculosis Ags were also unaffected. Dexamethasone does not appear to improve survival from TBM by attenuating immunological mediators of inflammation in the subarachnoid space or by suppressing peripheral T cell responses to mycobacterial Ags. These findings challenge previously held theories of corticosteroid action in this disease. An understanding of how dexamethasone acts in TBM may suggest novel and more effective treatment strategies.

Original languageEnglish
Pages (from-to)579-590
Number of pages12
JournalJournal of Immunology
Volume175
Issue number1
DOIs
Publication statusPublished - 1 Jul 2005

Cite this

Simmons, Cameron P. ; Thwaites, Guy E. ; Quyen, Nguyen Than Ha ; Chau, Tran Thi Hong ; Mai, Pham Phuong ; Dung, Nguyen Thi ; Stepniewska, Kasia ; White, Nicholas J. ; Hien, Tran Tinh ; Farrar, Jeremy. / The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. In: Journal of Immunology. 2005 ; Vol. 175, No. 1. pp. 579-590.
@article{74706c89ff7b419bab23f104a66d241e,
title = "The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses",
abstract = "Outcome from tuberculous meningitis (TBM) is believed to be dependent on the severity of the intracerebral inflammatory response. We have recently shown that dexamethasone improved survival in adults with TBM and postulated that the clinical effect would be associated with a measurable systemic and intracerebral impact on immunological markers of inflammation. Prolonged inflammatory responses were detected in all TBM patients irrespective of treatment assignment (placebo or dexamethasone). The inflammatory response in the cerebrospinal fluid was characterized by a leukocytosis (predominantly CD3+CD4 + T lymphocytes, phenotypically distinct from those in the peripheral blood), elevated concentrations of inflammatory and anti-inflammatory cytokines, chemokines, and evidence of prolonged blood-brain barrier dysfunction. Dexamethasone significantly modulated acute cerebrospinal fluid protein concentrations and marginally reduced IFN-γ concentrations; other immunological and routine biochemical indices of inflammation were unaffected. Peripheral blood monocyte and T cell responses to Mycobacterium tuberculosis Ags were also unaffected. Dexamethasone does not appear to improve survival from TBM by attenuating immunological mediators of inflammation in the subarachnoid space or by suppressing peripheral T cell responses to mycobacterial Ags. These findings challenge previously held theories of corticosteroid action in this disease. An understanding of how dexamethasone acts in TBM may suggest novel and more effective treatment strategies.",
author = "Simmons, {Cameron P.} and Thwaites, {Guy E.} and Quyen, {Nguyen Than Ha} and Chau, {Tran Thi Hong} and Mai, {Pham Phuong} and Dung, {Nguyen Thi} and Kasia Stepniewska and White, {Nicholas J.} and Hien, {Tran Tinh} and Jeremy Farrar",
year = "2005",
month = "7",
day = "1",
doi = "10.4049/jimmunol.175.1.579",
language = "English",
volume = "175",
pages = "579--590",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. / Simmons, Cameron P.; Thwaites, Guy E.; Quyen, Nguyen Than Ha; Chau, Tran Thi Hong; Mai, Pham Phuong; Dung, Nguyen Thi; Stepniewska, Kasia; White, Nicholas J.; Hien, Tran Tinh; Farrar, Jeremy.

In: Journal of Immunology, Vol. 175, No. 1, 01.07.2005, p. 579-590.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses

AU - Simmons, Cameron P.

AU - Thwaites, Guy E.

AU - Quyen, Nguyen Than Ha

AU - Chau, Tran Thi Hong

AU - Mai, Pham Phuong

AU - Dung, Nguyen Thi

AU - Stepniewska, Kasia

AU - White, Nicholas J.

AU - Hien, Tran Tinh

AU - Farrar, Jeremy

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Outcome from tuberculous meningitis (TBM) is believed to be dependent on the severity of the intracerebral inflammatory response. We have recently shown that dexamethasone improved survival in adults with TBM and postulated that the clinical effect would be associated with a measurable systemic and intracerebral impact on immunological markers of inflammation. Prolonged inflammatory responses were detected in all TBM patients irrespective of treatment assignment (placebo or dexamethasone). The inflammatory response in the cerebrospinal fluid was characterized by a leukocytosis (predominantly CD3+CD4 + T lymphocytes, phenotypically distinct from those in the peripheral blood), elevated concentrations of inflammatory and anti-inflammatory cytokines, chemokines, and evidence of prolonged blood-brain barrier dysfunction. Dexamethasone significantly modulated acute cerebrospinal fluid protein concentrations and marginally reduced IFN-γ concentrations; other immunological and routine biochemical indices of inflammation were unaffected. Peripheral blood monocyte and T cell responses to Mycobacterium tuberculosis Ags were also unaffected. Dexamethasone does not appear to improve survival from TBM by attenuating immunological mediators of inflammation in the subarachnoid space or by suppressing peripheral T cell responses to mycobacterial Ags. These findings challenge previously held theories of corticosteroid action in this disease. An understanding of how dexamethasone acts in TBM may suggest novel and more effective treatment strategies.

AB - Outcome from tuberculous meningitis (TBM) is believed to be dependent on the severity of the intracerebral inflammatory response. We have recently shown that dexamethasone improved survival in adults with TBM and postulated that the clinical effect would be associated with a measurable systemic and intracerebral impact on immunological markers of inflammation. Prolonged inflammatory responses were detected in all TBM patients irrespective of treatment assignment (placebo or dexamethasone). The inflammatory response in the cerebrospinal fluid was characterized by a leukocytosis (predominantly CD3+CD4 + T lymphocytes, phenotypically distinct from those in the peripheral blood), elevated concentrations of inflammatory and anti-inflammatory cytokines, chemokines, and evidence of prolonged blood-brain barrier dysfunction. Dexamethasone significantly modulated acute cerebrospinal fluid protein concentrations and marginally reduced IFN-γ concentrations; other immunological and routine biochemical indices of inflammation were unaffected. Peripheral blood monocyte and T cell responses to Mycobacterium tuberculosis Ags were also unaffected. Dexamethasone does not appear to improve survival from TBM by attenuating immunological mediators of inflammation in the subarachnoid space or by suppressing peripheral T cell responses to mycobacterial Ags. These findings challenge previously held theories of corticosteroid action in this disease. An understanding of how dexamethasone acts in TBM may suggest novel and more effective treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=21244456366&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.175.1.579

DO - 10.4049/jimmunol.175.1.579

M3 - Article

VL - 175

SP - 579

EP - 590

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -